Head to Head Comparison: Ligand Pharmaceuticals (NASDAQ:LGND) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

Ligand Pharmaceuticals (NASDAQ:LGND) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.

Earnings and Valuation

This table compares Ligand Pharmaceuticals and Kiniksa Pharmaceuticals International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$290.54 million	20.56	$124.45 million	$9.35	32.05
Kiniksa Pharmaceuticals International	$677.56 million	9.08	$59.01 million	$0.97	81.28

Ligand Pharmaceuticals has higher earnings, but lower revenue than Kiniksa Pharmaceuticals International. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ligand Pharmaceuticals and Kiniksa Pharmaceuticals International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	67.88%	20.06%	11.68%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Institutional & Insider Ownership

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. Comparatively, 53.9% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 5.6% of Ligand Pharmaceuticals shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Ligand Pharmaceuticals has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Ligand Pharmaceuticals and Kiniksa Pharmaceuticals International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0	0	10	0	3.00
Kiniksa Pharmaceuticals International	0	1	8	0	2.89

Ligand Pharmaceuticals presently has a consensus target price of $337.89, suggesting a potential upside of 12.76%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, suggesting a potential upside of 18.13%. Given Kiniksa Pharmaceuticals International’s higher probable upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Ligand Pharmaceuticals.

Summary

Ligand Pharmaceuticals beats Kiniksa Pharmaceuticals International on 10 of the 14 factors compared between the two stocks.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.